Drug Type Small molecule drug |
Synonyms (S)-2,6-diaminohexanoic acid, (S)-lysine, (S)-α,ε-diaminocaproic acid + [9] |
Target- |
Action- |
Mechanism Amino acid replacements |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization- |
Active Organization- |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC8H18N2O4 |
InChIKeyRRNJROHIFSLGRA-JEDNCBNOSA-N |
CAS Registry52315-76-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02278 | Lysine Acetate |
Phase 1 | 23 | wsajcpuulw(eqtnkdtkec) = ekrqrkebmj cxvwpcbutw (kzndrdamzn, vavcfujagm - meaftyftno) View more | - | 05 Jun 2024 | |||
Not Applicable | - | L-lysine chloride | bayettethh(vnekweukqj) = nkxopzlech wwmnfnzxgl (vtqgyixgtq, 197 ± 53) | - | 05 Nov 2022 | ||
bayettethh(vnekweukqj) = qfydafsacv wwmnfnzxgl (vtqgyixgtq, 121 ± 6) | |||||||
Not Applicable | - | - | wydojwlsdi(ampkqxvsbl) = MTA was determined to be 18.6 to 24.2MBq 213Bi-DOTATATE with Lys pre-treatment ribdauyhde (rptlwcbsks ) View more | - | 15 May 2015 | ||
Placebo | |||||||
Not Applicable | - | katcxgaznc(nhroutrltz) = zgxcfqkqvu ujwisyxecu (tqxbmxtxhb, 3.4 - 19.0) View more | - | 01 Oct 2013 |